Updates

October 23, 2020October 23, 2020
FDA Supports Cala Trio as Potential Therapy for Action Tremors in Hands

The U.S. Food and Drug Administration (FDA) has named Cala Trio a breakthrough device as a potential wrist-worn treatment of action tremors in the hands of adults with Parkinson’s disease. ... Read more
October 23, 2020October 21, 2020
Parkinson’s Disease Remission: Can the Conductor Help?

In previous columns, I have discussed using the conductor (in particular, the resting mind state) to suppress faulty input from the second dopamine center, thus ... Read more
October 23, 2020October 23, 2020
Sanofi Supports PD GENEration Initiative to Increase Genetic Testing of Parkinson’s Patients

Sanofi will provide $1 million in research funding over the next two years to support PD GENEration, a national initiative seeking to increase the ... Read more
October 22, 2020October 21, 2020
Wobbly and Stone-faced: The Misunderstood Symptoms of Parkinson’s

Several years ago, I read an article about a man with Parkinson’s disease who was arrested by police in Surrey, England due to a ... Read more
October 22, 2020October 22, 2020
Phase 2b Trial of Prasinezumab in Patients With Early Parkinson’s Expected by 2021

Roche, in partnership with Prothena, will launch a Phase 2b clinical trial to evaluate the effectiveness of prasinezumab (PRX002/RG7935) — an antibody against the alpha-synuclein protein — in ... Read more

Subscribe to our mailing list

Get regular updates delivered to your email box.

Thanks! Please check your email for a confirmation email.

June 22, 2018June 22, 2018

New Tool Effectively Monitors Sleep Quality in Parkinson’s Patients, Researchers Say

News

A new tool called cardiopulmonary coupling could be used to effectively evaluate sleep quality in Parkinson’s disease patients, who often experience sleep disorders, according to a study. The study, “Assessment of sleep quality using cardiopulmonary coupling analysis in patients with ... Read more

FDA Supports Cala Trio as Potential Therapy for Action Tremors in Hands

Parkinson’s Disease Remission: Can the Conductor Help?

Sanofi Supports PD GENEration Initiative to Increase Genetic Testing of Parkinson’s Patients

Wobbly and Stone-faced: The Misunderstood Symptoms of Parkinson’s

Phase 2b Trial of Prasinezumab in Patients With Early Parkinson’s Expected by 2021

Taking a Closer Look at a First-ever Parkinson’s Stem Cell Study

Imbalance of Fat Content in Brain Cells May Fuel Parkinson’s Progression, Study Asserts

Gut Bacteria May Cause Constipation Associated With Levodopa in Parkinson’s Patients

Chemical-electrical Brain Signals Link More Complex Than Thought, Study Finds

Anti-inflammatory Therapies May Alter Disease Course in Patients With Early-onset Parkinson’s, Study Suggests

Buspirone Eases Anxiety, But Tolerability Seen as Problem in Small Trial

Subscribe to our mailing list

Pharmather to Advance Ketamine as Potential Dyskinesia Treatment

Anavex 2-73 Safely Aids Cognition in Parkinson’s Dementia, Phase 2 Trial Reports

The Default Mode Network: Lies From the Insular Cortex

Neurons in Cell Cultures Form Complicated Networks, Study Shows

Dopamine and Serotonin Play Key Role in Perception and Cognition, Study Finds

Certain Diabetes Medications Linked to Lower Parkinson’s Risk, Study Suggests

Study Delves Into Genetic, Environmental Risk Factors for Parkinson’s

MJFF, Acadia Partner to Heighten Awareness of Non-motor Parkinson’s Symptoms

Innovative Tool Identifies New Alpha-synuclein PET Tracers for Parkinson’s

CLR01 ‘Molecular Tweezer’ Shows Potential to Slow Parkinson’s Progression

Risk of Recurrent Falls Evident in Elderly With Gait, Cognitive Problems

Rebuilding Your Life With Hope

Discovery of Key Feature of Alpha-synuclein May Lead to New Treatment Strategies for Parkinson’s

Parkinson’s Foundation, Amazon’s Alexa Partner to Share Quality Information

The Insular Cortex Dopamine Center and Its Relationship to Parkinson’s

Parkinson’s Patients at Greater Risk of Dying from COVID-19, Study Suggests

STADA Acquires Triple Combo Pump Therapy, Seeks European Approvals

Sewing and Stitching With Parkinson’s

AXO-Lenti-PD Gene Therapy Showing Benefits in 2nd SUNRISE-PD Group

Ongentys Seen to Shorten Overnight ‘Off’ Periods, Lengthen Good ‘On’ Time

Counting My Blessings as the Seasons Change

Kynmobi Sublingual Film for ‘Off’ Episodes Now Available in US

Caffeine May Also Protect Against Parkinson’s Due to LRRK2 Mutations

Adopting a New Mantra to Stay Positive

New Data Support Effectiveness of Ongentys for Parkinson’s ‘Off’ Periods

BIAL Acquires Parkinson’s Treatment LTI-291, Opens US Research Center

FDA Accepts New Drug Application for IRLAB’s Mesdopetam for Dyskinesia

My Parkinson’s Portrait Is Outside the Classic Criteria